Insider buying · SEC Form 4

LTGO insider buying

Open-market purchases of Latigo Biotherapeutics, Inc. (LTGO) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.

1insider buy on record
$2.52Mbought in total
1insider
0by CEOs, CFOs and other chiefs
Aug 11, 2026latest scan with a buy

Every recorded buy

ScanInsiderValueSharesAvg priceTypeFiled
Aug 11, 2026James B. TananbaumDirector, 10% Owner$2.52M140,000$18.00AddedAug 10, 2026
Form 4 ↗
IPO-day purchase at offering price ($18.00). Foresite Capital held ~15% post-IPO stake from pre-IPO preferred; this adds 140,000 shares of common at the offering close. Latigo raised $345.6M for non-opioid pain pipeline (Nav1.8 inhibitor). Now $18.56 (+3.1% from buy).

Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.

SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →

See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.

Open the live chartOpen in the Stocks tab

© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.